|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hormone/growth factor
|
 |
|
Title:
|
 |
Crystal structure of a ternary ligand-receptor complex of bmp-2
|
|
Structure:
|
 |
Bone morphogenetic protein 2. Chain: a, b. Synonym: bmp-2, bmp-2a. Engineered: yes. Bone morphogenetic protein receptor type ia. Chain: c. Fragment: extracellular domain. Synonym: serine/threonine-protein kinase receptor r5, skr5, activin receptor-like kinase 3, alk-3, cd292 antigen.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: bmp2, bmp2a. Expressed in: escherichia coli. Expression_system_taxid: 562. Gene: bmpr1a, acvrlk3, alk3. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
1.85Å
|
R-factor:
|
0.216
|
R-free:
|
0.225
|
|
|
Authors:
|
 |
T.D.Mueller
|
|
Key ref:
|
 |
D.Weber
et al.
(2007).
A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.
Bmc Struct Biol,
7,
6.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
30-May-06
|
Release date:
|
10-Apr-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P12643
(BMP2_HUMAN) -
Bone morphogenetic protein 2
|
|
|
|
Seq: Struc:
|
 |
 |
 |
396 a.a.
104 a.a.
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains C, D:
E.C.2.7.11.30
- Receptor protein serine/threonine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + [receptor-protein] = ADP + [receptor-protein] phosphate
|
 |
 |
 |
 |
 |
ATP
|
+
|
[receptor-protein]
|
=
|
ADP
|
+
|
[receptor-protein] phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
2 terms
|
 |
|
Biological process
|
transmembrane receptor protein serine/threonine kinase signaling pathway
|
1 term
|
 |
|
Biochemical function
|
growth factor activity
|
5 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bmc Struct Biol
7:6
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.
|
|
D.Weber,
A.Kotzsch,
J.Nickel,
S.Harth,
A.Seher,
U.Mueller,
W.Sebald,
T.D.Mueller.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: Bone morphogenetic proteins (BMPs) are key regulators in the
embryonic development and postnatal tissue homeostasis in all animals. Loss of
function or dysregulation of BMPs results in severe diseases or even lethality.
Like transforming growth factors beta (TGF-betas), activins, growth and
differentiation factors (GDFs) and other members of the TGF-beta superfamily,
BMPs signal by assembling two types of serine/threonine-kinase receptor chains
to form a hetero-oligomeric ligand-receptor complex. BMP ligand receptor
interaction is highly promiscuous, i.e. BMPs bind more than one receptor of each
subtype, and a receptor bind various ligands. The activin type II receptors are
of particular interest, since they bind a large number of diverse ligands. In
addition they act as high-affinity receptors for activins but are also
low-affinity receptors for BMPs. ActR-II and ActR-IIB therefore represent an
interesting example how affinity and specificity might be generated in a
promiscuous background. RESULTS: Here we present the high-resolution structures
of the ternary complexes of wildtype and a variant BMP-2 bound to its
high-affinity type I receptor BMPR-IA and its low-affinity type II receptor
ActR-IIB and compare them with the known structures of binary and ternary
ligand-receptor complexes of BMP-2. In contrast to activin or TGF-beta3 no
changes in the dimer architecture of the BMP-2 ligand occur upon complex
formation. Functional analysis of the ActR-IIB binding epitope shows that
hydrophobic interactions dominate in low-affinity binding of BMPs; polar
interactions contribute only little to binding affinity. However, a conserved
H-bond in the center of the type II ligand-receptor interface, which does not
contribute to binding in the BMP-2 - ActR-IIB interaction can be mutationally
activated resulting in a BMP-2 variant with high-affinity for ActR-IIB. Further
mutagenesis studies were performed to elucidate the binding mechanism allowing
us to construct BMP-2 variants with defined type II receptor binding properties.
CONCLUSION: Binding specificity of BMP-2 for its three type II receptors
BMPR-II, Act-RII and ActR-IIB is encoded on single amino acid level. Exchange of
only one or two residues results in BMP-2 variants with a dramatically altered
type II receptor specificity profile, possibly allowing construction of BMP-2
variants that address a single type II receptor. The structure-/function studies
presented here revealed a new mechanism, in which the energy contribution of a
conserved H-bond is modulated by surrounding intramolecular interactions to
achieve a switch between low- and high-affinity binding.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.J.Lubbe,
A.M.Pittman,
C.Matijssen,
P.Twiss,
B.Olver,
A.Lloyd,
M.Qureshi,
N.Brown,
E.Nye,
G.Stamp,
J.Blagg,
and
R.S.Houlston
(2011).
Evaluation of germline BMP4 mutation as a cause of colorectal cancer.
|
| |
Hum Mutat, 32,
E1928-E1938.
|
 |
|
|
|
|
 |
C.C.Rider,
and
B.Mulloy
(2010).
Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists.
|
| |
Biochem J, 429,
1.
|
 |
|
|
|
|
 |
L.Calvanese,
D.Marasco,
N.Doti,
A.Saporito,
G.D'Auria,
L.Paolillo,
M.Ruvo,
and
L.Falcigno
(2010).
Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach.
|
| |
Biopolymers, 93,
1011-1021.
|
 |
|
|
|
|
 |
O.F.Zouani,
C.Chollet,
B.Guillotin,
and
M.C.Durrieu
(2010).
Differentiation of pre-osteoblast cells on poly(ethylene terephthalate) grafted with RGD and/or BMPs mimetic peptides.
|
| |
Biomaterials, 31,
8245-8253.
|
 |
|
|
|
|
 |
S.Harth,
A.Kotzsch,
J.Hu,
W.Sebald,
and
T.D.Mueller
(2010).
A selection fit mechanism in BMP receptor IA as a possible source for BMP ligand-receptor promiscuity.
|
| |
PLoS One, 5,
0.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
W.J.Kuo,
M.A.Digman,
and
A.D.Lander
(2010).
Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization.
|
| |
Mol Biol Cell, 21,
4028-4041.
|
 |
|
|
|
|
 |
Z.Xu,
X.W.Liu,
Y.S.Ma,
and
H.W.Gao
(2010).
Interaction of nano-TiO(2) with lysozyme: insights into the enzyme toxicity of nanosized particles.
|
| |
Environ Sci Pollut Res Int, 17,
798-806.
|
 |
|
|
|
|
 |
A.Kotzsch,
J.Nickel,
A.Seher,
W.Sebald,
and
T.D.Müller
(2009).
Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity.
|
| |
EMBO J, 28,
937-947.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.N.Cash,
C.A.Rejon,
A.C.McPherron,
D.J.Bernard,
and
T.B.Thompson
(2009).
The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding.
|
| |
EMBO J, 28,
2662-2676.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Nickel,
W.Sebald,
J.C.Groppe,
and
T.D.Mueller
(2009).
Intricacies of BMP receptor assembly.
|
| |
Cytokine Growth Factor Rev, 20,
367-377.
|
 |
|
|
|
|
 |
K.Heinecke,
A.Seher,
W.Schmitz,
T.D.Mueller,
W.Sebald,
and
J.Nickel
(2009).
Receptor oligomerization and beyond: a case study in bone morphogenetic proteins.
|
| |
BMC Biol, 7,
59.
|
 |
|
|
|
|
 |
M.H.Alaoui-Ismaili,
and
D.Falb
(2009).
Design of second generation therapeutic recombinant bone morphogenetic proteins.
|
| |
Cytokine Growth Factor Rev, 20,
501-507.
|
 |
|
|
|
|
 |
S.C.Little,
and
M.C.Mullins
(2009).
Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis.
|
| |
Nat Cell Biol, 11,
637-643.
|
 |
|
|
|
|
 |
A.Galat,
G.Gross,
P.Drevet,
A.Sato,
and
A.Ménez
(2008).
Conserved structural determinants in three-fingered protein domains.
|
| |
FEBS J, 275,
3207-3225.
|
 |
|
|
|
|
 |
J.Groppe,
C.S.Hinck,
P.Samavarchi-Tehrani,
C.Zubieta,
J.P.Schuermann,
A.B.Taylor,
P.M.Schwarz,
J.L.Wrana,
and
A.P.Hinck
(2008).
Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding.
|
| |
Mol Cell, 29,
157-168.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Y.Qiu,
J.L.Zhang,
A.Kotzsch,
W.Sebald,
and
T.D.Mueller
(2008).
Crystallization and preliminary X-ray analysis of the complex of the first von Willebrand type C domain bound to bone morphogenetic protein 2.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 64,
307-312.
|
 |
|
|
|
|
 |
R.Stamler,
H.T.Keutmann,
Y.Sidis,
C.Kattamuri,
A.Schneyer,
and
T.B.Thompson
(2008).
The Structure of FSTL3{middle dot}Activin A Complex: DIFFERENTIAL BINDING OF N-TERMINAL DOMAINS INFLUENCES FOLLISTATIN-TYPE ANTAGONIST SPECIFICITY.
|
| |
J Biol Chem, 283,
32831-32838.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.L.Zhang,
Y.Huang,
L.Y.Qiu,
J.Nickel,
and
W.Sebald
(2007).
von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms.
|
| |
J Biol Chem, 282,
20002-20014.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
| |